NASDAQ:ARNA - Arena Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.36
  • Forecasted Upside: 11.25 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$81.22
▲ +0.52 (0.64%)
1 month | 3 months | 12 months
Get New Arena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$90.36
▲ +11.25% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $90.36, with a high forecast of $120.00 and a low forecast of $62.00. The average price target represents a 11.25% upside from the last price of $81.22.
Buy
The current consensus among 14 contributing investment analysts is to buy stock in Arena Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageOutperform$100.00Low
i
11/19/2020Smith Barney CitigroupInitiated CoverageOutperform$100.00Medium
i
11/10/2020GuggenheimLower Price TargetBuy$115.00 ➝ $105.00High
i
11/10/2020Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$80.00 ➝ $76.00High
i
11/10/2020SVB LeerinkBoost Price TargetOutperform$91.00 ➝ $92.00High
i
11/2/2020JPMorgan Chase & Co.Boost Price Target$71.00 ➝ $90.00Medium
i
10/13/2020Cantor FitzgeraldBoost Price Target$88.00 ➝ $110.00Low
i
9/30/2020Bank of AmericaBoost Price TargetBuy$75.00 ➝ $85.00Medium
i
9/18/2020CitigroupBoost Price TargetBuy$83.00 ➝ $120.00Medium
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
i
8/17/2020GuggenheimBoost Price TargetBuy$95.00 ➝ $115.00Low
i
8/6/2020HC WainwrightReiterated RatingBuy$90.00High
i
Rating by Patrick Trucchio at HC Wainwright
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$60.00 ➝ $78.00Low
i
8/6/2020SVB LeerinkBoost Price TargetOutperform$73.00 ➝ $91.00Low
i
8/6/2020Needham & Company LLCReiterated RatingBuy$70.00Low
i
7/27/2020CitigroupBoost Price TargetBuy$65.00 ➝ $83.00Medium
i
6/29/2020HC WainwrightInitiated CoverageBuy$90.00High
i
Rating by P. Trucchio at HC Wainwright
6/2/2020Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$77.00 ➝ $87.00Medium
i
5/18/2020Jefferies Financial GroupInitiated CoverageBuy$62.00High
i
5/8/2020Cantor FitzgeraldReiterated RatingBuy$56.00 ➝ $68.00Low
i
4/14/2020Needham & Company LLCReiterated RatingBuy$70.00High
i
3/31/2020GuggenheimInitiated CoverageBuy$95.00Low
i
3/26/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $56.00High
i
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$62.00 ➝ $56.00High
i
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$58.00High
i
1/27/2020Royal Bank of CanadaReiterated RatingBuy$83.00Medium
i
11/14/2019Wood & CompanyReiterated RatingSellMedium
i
11/13/2019Bank of AmericaInitiated CoverageNeutral$51.00Low
i
8/11/2019Royal Bank of CanadaReiterated RatingBuy$79.00High
i
5/8/2019Cantor FitzgeraldReiterated RatingBuyHigh
i
Rating by A. Young at Cantor Fitzgerald
4/3/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$63.00 ➝ $77.00High
i
2/26/2019Cantor FitzgeraldReiterated RatingBuy$62.00High
i
Rating by A. Young at Cantor Fitzgerald
1/28/2019Cantor FitzgeraldReiterated RatingBuy$62.00Low
i
Rating by A. Young at Cantor Fitzgerald
12/13/2018Berenberg BankInitiated CoverageBuy ➝ Buy$55.00Low
i
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by A. Young at Cantor Fitzgerald
11/19/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$56.00 ➝ $61.00Low
i
11/16/2018Royal Bank of CanadaBoost Price TargetOutperform$70.00Low
i
11/15/2018Needham & Company LLCSet Price TargetBuy$60.00High
i
Rating by Alan Carr at Needham & Company LLC
11/15/2018Cantor FitzgeraldSet Price TargetBuy$65.00Low
i
Rating by William Tanner at Cantor Fitzgerald
11/7/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
i
Rating by William Tanner at Cantor Fitzgerald
9/24/2018Cantor FitzgeraldSet Price TargetBuy$65.00High
i
Rating by William Tanner at Cantor Fitzgerald
8/7/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$58.00 ➝ $56.00High
i
5/31/2018Royal Bank of CanadaInitiated CoverageOutperform$65.00Medium
i
3/21/2018CitigroupReiterated RatingPositive ➝ Buy$62.00High
i
3/20/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$63.00 ➝ $79.00High
i
3/20/2018Wells Fargo & CompanyLower Price TargetPositive ➝ Outperform$53.00 ➝ $60.00High
i
3/20/2018Needham & Company LLCUpgradeHold ➝ Buy$30.89 ➝ $60.00High
i
3/14/2018Needham & Company LLCReiterated RatingHoldHigh
i
2/27/2018CitigroupBoost Price TargetBuy ➝ Buy$37.00 ➝ $55.00High
i
2/20/2018JMP SecuritiesBoost Price TargetOutperform$36.00 ➝ $63.00Low
i
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$44.00Low
i
1/17/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$53.00 ➝ $56.00Low
i
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
i
1/3/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
i
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00High
i
Rating by W. Tanner at Cantor Fitzgerald
8/8/2017Needham & Company LLCReiterated RatingHoldMedium
i
7/17/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Low
i
Rating by W. Tanner at Cantor Fitzgerald
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 ➝ $19.00Medium
i
7/11/2017CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00Low
i
7/11/2017SVB LeerinkBoost Price TargetOutperform$47.00 ➝ $53.00High
i
Rating by J. Schwartz at SVB Leerink LLC
7/7/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$27.00 ➝ $27.00High
i
6/30/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Medium
i
Rating by W. Tanner at Cantor Fitzgerald
6/27/2017CitigroupInitiated CoverageBuy ➝ Buy$23.00Medium
i
6/15/2017Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by W. Tanner at Cantor Fitzgerald
5/19/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$50.00High
i
Rating by J. Schwartz at SVB Leerink LLC
3/16/2017(FBRC)Reiterated RatingOutperform$60.00Medium
i
Rating by R. Jasuja at (FBRC)
1/23/2017(FBRC)Reiterated RatingOutperformN/A
i
Rating by R. Jasuja at (FBRC)
1/7/2017Needham & Company LLCReiterated RatingHoldN/A
i
11/10/2016Needham & Company LLCReiterated RatingHoldN/A
i
11/9/2016(FBRC)Reiterated RatingBuy$60.00N/A
i
Rating by christopher james at (FBRC)
9/15/2016(FBRC)Initiated CoverageOutperform$60.00N/A
i
Rating by C. James at (FBRC)
8/13/2016Needham & Company LLCReiterated RatingHoldN/A
i
8/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
Rating by jessica fye at JPMorgan Chase & Co.
5/10/2016Wells Fargo & CompanyReiterated RatingHoldN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
3/1/2016Royal Bank of CanadaReiterated RatingSector Perform$20.00 ➝ $15.00N/A
i
1/27/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
(Data available from 1/20/2016 forward)
Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More

Today's Range

Now: $81.22
$80.34
$81.75

50 Day Range

MA: $74.38
$65.31
$80.70

52 Week Range

Now: $81.22
$32.95
$90.19

Volume

466,974 shs

Average Volume

486,100 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Arena Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, and Wells Fargo & Company.

What is the current price target for Arena Pharmaceuticals?

14 Wall Street analysts have set twelve-month price targets for Arena Pharmaceuticals in the last year. Their average twelve-month price target is $90.36, suggesting a possible upside of 12.0%. Citigroup Inc. has the highest price target set, predicting ARNA will reach $120.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $62.00 for Arena Pharmaceuticals in the next year.

What is the current consensus analyst rating for Arena Pharmaceuticals?

Arena Pharmaceuticals currently has 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARNA will outperform the market and that investors should add to their positions of Arena Pharmaceuticals.

What other companies compete with Arena Pharmaceuticals?

How do I contact Arena Pharmaceuticals' investor relations team?

Arena Pharmaceuticals' physical mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company's listed phone number is 858-453-7200 and its investor relations email address is ir@arenapharm.com. The official website for Arena Pharmaceuticals is www.arenapharm.com.